Axis Bio
Axis Bio, a QIMA Life Sciences Company, is a specialist preclinical oncology CRO with over a decade of in vivo tumour model expertise, and an emphasis scientist-led bespoke study design, and a lean structure built for speed and flexibility. Its portfolio includes validated CDX models across over 17 cancer types (including rare subtypes), syngeneic immuno-oncology models, humanised mouse studies, and orthotopic/disseminated tumour imaging via luciferase-expressing lines. Since joining QIMA Life Sciences in 2025, Axis Bio also draws on deep in vitro and ex vivo immunology expertise.
